Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

Hellmann, M.; Paz-Ares, L.; Bernabé Caro, R.; Żurawski, B.; Kim, Sang-We; Carcereny Costa, E.; Park, Keunchil; Alexandru, A.; Lupinacci, L.; de la Mora Jimenez, Emmanuel; Sakai, H.; Albert, I.; Vergnenègre, A.; Peters, S.; Syrigos, K.; Barlesi, F.; Reck, M.; Borghaei, H.; Brahmer, J.; O'Byrne, K.; Geese, W.; Bhagavatheeswaran, P.; Rabindran, S.; Kasinathan, R.; Nathan, F.; Ramalingam, S.

doi:10.1056/NEJMoa1910231

Public

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

Shared by NobleBlocks on Sep 28, 2019 • 12:00 AM UTC

Authors:

M. Hellmann

L. Paz-Ares

R. Bernabé Caro

Abstract

BACKGROUND In an early-phase study involving patients with advanced non-small-cell lung cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with nivolumab monotherapy, particularly among patients with tumors that expressed programmed death ligand 1 (PD-L1). Data are need...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!